| 3.76 0.31 (8.99%) | 05-21 15:09 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.78 |
1-year : | 5.59 |
| Resists | First : | 4.09 |
Second : | 4.78 |
| Pivot price | 3.62 |
|||
| Supports | First : | 3.5 |
Second : | 3.13 |
| MAs | MA(5) : | 3.5 |
MA(20) : | 3.61 |
| MA(100) : | 3.17 |
MA(250) : | 2.43 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 54.6 |
D(3) : | 41.7 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 4.75 | Low : | 1.29 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADAG ] has closed below upper band by 21.2%. Bollinger Bands are 41.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.46 - 3.47 | 3.47 - 3.49 |
| Low: | 3.17 - 3.19 | 3.19 - 3.21 |
| Close: | 3.42 - 3.45 | 3.45 - 3.48 |
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Tue, 19 May 2026
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - TradingView
Fri, 15 May 2026
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Tue, 12 May 2026
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Tue, 12 May 2026
Cancer antibody developer Adagene speaks at two investor events - Stock Titan
Tue, 12 May 2026
Adagene to Participate in Two Upcoming Investor Conferences - ChartMill
Tue, 12 May 2026
Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 4.142e+007 (%) |
| Held by Institutions | 21.1 (%) |
| Shares Short | 71 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -229.6 % |
| Operating Margin | -75 % |
| Return on Assets (ttm) | -16 % |
| Return on Equity (ttm) | -34.4 % |
| Qtrly Rev. Growth | 7 % |
| Gross Profit (p.s.) | 583.85 |
| Sales Per Share | 1.34561e+007 |
| EBITDA (p.s.) | 1.34561e+007 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.86 |
| Dividend | 0 |
| Forward Dividend | 668770 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|